OBI1-AS1: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: OBI1-AS1

NCBI ID: G100874222

OBI1-AS1

Other Name(s): RNF219-AS1 | POU4F1-AS1 | OBI1 antisense RNA 1 | POU4F1 antisense RNA 1 (non-protein coding)

OBI1-AS1: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

OBI1-AS1 is a unique protein that has been identified as a potential drug target and biomarker for multiple chronic diseases. It is a transmembrane protein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. The protein is composed of 114 amino acids and has a molecular weight of 13.9 kDa. OBI1-AS1 is involved in various cellular processes, including cell signaling, neurotransmitter release, and inflammation.

The Importance of OBI1-AS1 as a Drug Target

OBI1-AS1 has been identified as a potential drug target due to its involvement in various cellular processes that are linked to the development and progression of chronic diseases. OBI1-AS1 is involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is known to play a role in the development of cancer, neurodegenerative diseases, and other chronic conditions.

In addition to its involvement in cell signaling pathways, OBI1-AS1 has also been shown to contribute to the development of chronic diseases. For example, studies have shown that OBI1-AS1 is involved in the regulation of insulin secretion and sensitivity, which is critical for maintaining proper glucose levels and preventing the development of type 2 diabetes.

OBI1-AS1 has also been shown to play a role in the regulation of pain perception and neuroinflammation. Chronic pain and neuroinflammation are major health concerns in the world today, and there is a high demand for effective treatments that can alleviate these symptoms. OBI1-AS1 may offer a new approach to treating these conditions as it has been shown to have potential in modulating pain perception and reducing neuroinflammation.

The Potential of OBI1-AS1 as a Biomarker

OBI1-AS1 may also have the potential as a biomarker for multiple chronic diseases. The protein has been shown to be expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. This suggests that it may be a useful biomarker for monitoring disease progression and assessing the effectiveness of treatments.

In addition, OBI1-AS1 has been shown to be involved in the regulation of cellular processes that are linked to the development and progression of chronic diseases. This suggests that it may be a useful biomarker for tracking the effectiveness of treatments and identifying potential new targets for further research.

Conclusion

OBI1-AS1 is a unique protein that has the potential to be a drug target and biomarker for multiple chronic diseases. Its involvement in various cellular processes, including cell signaling, neurotransmitter release, and inflammation, makes it an attractive target for drug development. In addition, its potential as a biomarker for multiple chronic diseases makes it an important addition to the toolkit for disease researchers. Further studies are needed to fully understand the role of OBI1-AS1 in the development and progression of chronic diseases.

Protein Name: OBI1 Antisense RNA 1

The "OBI1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OBI1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets